Effect of single intravitreal bevacizumab on ophthalmic and middle cerebral arterial blood flow in retinopathy of prematurity

dc.authorid0000-0002-8874-1473en_US
dc.authorid0000-0002-0024-8458
dc.authorid0000-0003-3952-9203
dc.authorid0000-0003-2111-0420
dc.authorid0000-0002-7467-2593
dc.contributor.authorGünay, Murat
dc.contributor.authorTüten, Abdulhamit
dc.contributor.authorSancak, Selim
dc.contributor.authorÇelik, Gökhan
dc.contributor.authorBardak, Handan
dc.date.accessioned2021-06-23T19:44:39Z
dc.date.available2021-06-23T19:44:39Z
dc.date.issued2016
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractPurpose: To evaluate the effect of a single intravitreal bevacizumab (IVB) injection on blood flow parameters in the ophthalmic artery (OA) and middle cerebral artery (MCA) in infants with retinopathy of prematurity (ROP). Materials and Methods: This prospective and interventional study included 15 infants with ROP who were treated with IVB. Peak systolic velocity (PSV), end-diastolic velocity, mean velocity (MV) and resistivity index were measured using pulse wave Doppler ultrasonography (Philips En Visor C, Amsterdam, The Netherlands) in the OA and MCA, before IVB injection and 1 day, 1 week and 1 month after IVB injection. Results: Measurements of PSV-OA, MV-OA and PSV-MCA showed significant changes after IVB treatment (p = 0.01, p = 0.02, p = 0.02, respectively). The PSV-OA measurements at 1 week and 1 month were significantly lower than the baseline PSV-OA measurement (p = 0.03 and p = 0.01, respectively). The MV-OA measurement was significantly lower at 1 month following IVB as compared to the baseline MV-OA measurement (p = 0.03). The PSV-MCA showed a significant decline 1 day after IVB injection (p = 0.03). Conclusions: The study demonstrated that IVB causes significant alterations in blood flow parameters in the OA and MCA predicted by Doppler ultrasonography in infants with ROP. (C) 2016 S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000443208
dc.identifier.endpage171en_US
dc.identifier.issn0030-3747
dc.identifier.issn1423-0259
dc.identifier.issue4en_US
dc.identifier.pmid26820969en_US
dc.identifier.scopus2-s2.0-84955612507en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage165en_US
dc.identifier.urihttps://doi.org/10.1159/000443208
dc.identifier.urihttps://hdl.handle.net/20.500.12491/9022
dc.identifier.volume55en_US
dc.identifier.wosWOS:000373248700001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorSancak, Selim
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOphthalmic Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBlood Flowen_US
dc.subjectIntravitreal Bevacizumab Injectionen_US
dc.subjectDoppler Ultrasonographyen_US
dc.subjectMiddle Cerebral Arteryen_US
dc.subjectOphthalmic Arteryen_US
dc.subjectRetinopathy of Prematurityen_US
dc.titleEffect of single intravitreal bevacizumab on ophthalmic and middle cerebral arterial blood flow in retinopathy of prematurityen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
murat-gunay.pdf
Boyut:
272.39 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text